Omeros (OMER) Enterprise Value (2010 - 2026)
Omeros (OMER) posted Enterprise Value of -$135.3 million for Q1 2026, up 21.24% sequentially from -$171.8 million in Q4 2025, and down 158.18% YoY from $232.6 million in Q1 2025.
Analysis
Omeros (OMER) Enterprise Value (2010 - 2026) Analysis & Trends
Omeros has reported Enterprise Value for 17 years, with the latest figure at -$135.3 million in Q1 2026.
- Quarterly Enterprise Value fell 158.18% year-over-year to -$135.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$135.3 million (down 158.18% YoY) and the FY2025 annual result came in at -$171.8 million, down 90.61% from the prior year.
- Enterprise Value advanced to -$135.3 million in Q1 2026 per OMER's latest filing, from -$171.8 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$52.4 million in Q1 2025 and troughed at -$590.0 million in Q3 2023.
- A 5-year average of -$204.2 million and a median of -$158.9 million in 2024 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2023 and 2025: Enterprise Value tumbled 178.53% in 2023, then jumped 88.58% in 2025.
- Over 5 years, Enterprise Value stood at -$194.9 million in 2022, then rose by 11.84% to -$171.8 million in 2023, then jumped by 47.55% to -$90.1 million in 2024, then slumped by 90.61% to -$171.8 million in 2025, then advanced by 21.24% to -$135.3 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$135.3 million, -$171.8 million, and -$69.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 10 | Omeros | 1.37 Bn | 1.37 Bn | 27.73 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 553.60 Mn |
| Mar 31, 2026 | 624.99 Mn |
| Dec 31, 2025 | 1.06 Bn |
| Sep 30, 2025 | 217.51 Mn |
| Jun 30, 2025 | 124.53 Mn |
| Mar 31, 2025 | 376.74 Mn |
| Dec 31, 2024 | 483.35 Mn |
| Sep 30, 2024 | -14.78 Mn |
| Jun 30, 2024 | -80.44 Mn |
| Mar 31, 2024 | -258.90 Mn |
| Dec 31, 2023 | 28.04 Mn |
| Sep 30, 2023 | -406.40 Mn |
| Jun 30, 2023 | -334.09 Mn |
| Mar 31, 2023 | -446.77 Mn |
| Dec 31, 2022 | -52.92 Mn |
| Sep 30, 2022 | -98.83 Mn |
| Jun 30, 2022 | -58.52 Mn |
| Mar 31, 2022 | 101.54 Mn |
| Dec 31, 2021 | 245.44 Mn |
| Sep 30, 2021 | 769.10 Mn |